A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs PF 6651600 (Primary) ; PF 6700841 (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- Sponsors Pfizer
- 18 May 2017 Planned End Date changed from 27 May 2018 to 24 Jun 2018.
- 18 May 2017 Planned primary completion date changed from 27 May 2018 to 24 Jun 2018.
- 17 Jan 2017 Status changed from not yet recruiting to recruiting.